Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases

Seres previously reported exploratory translational biomarker data from its SER-155 Phase 1b study, which provided evidence supporting the intended therapeutic mechanisms. These included promoting intestinal epithelial barrier integrity to reduce the translocation of bacteria and inflammatory bacterial products into the bloodstream, as well as modulating systemic inflammatory responses. New results presented at the DDW conference could help identify candidate biomarkers to support the further clinical devel ...